Table 4.
Biomarker Analysis and Relation with DFS and OS.
| Variable | Score | n | DFS |
OS |
||
|---|---|---|---|---|---|---|
| HR⁎ (95% CI) | P⁎ | HR⁎ (95% CI) | P⁎ | |||
| CEP17 | Normal | 124 | 1 | 1 | ||
| Duplicated | 13 | 2.64 (0.64-10.9) | .179 | 2.42 (0.58-10.02) | .223 | |
| HER2 | Normal | 113 | 1 | 1 | ||
| Amplified | 24 | 0.97 (0.45-2.08) | .960 | 0.96 (0.44-2.06) | .907 | |
| TOP2A | Non-amplified | 130 | 1 | 1 | ||
| Amplified | 7 | 21.9 (0.92-5275) | .269 | 21.73 (0.04-11545) | .336 | |
| Ki67 | ≥ 20% | 60 | 1 | 1 | ||
| < 20% | 74 | 1.89 (1.04-3.46) | .036 | 1.91 (1.02-3.58) | .044 | |
| TOP2A/CEP17† | Normal | 117 | 1 | 1 | ||
| Altered | 20 | 4.35 (1.05-17.93) | .042 | 3.71 (0.89-15.34) | .071 | |
⁎
Univariable Cox proportional hazard models based on 136 patients, 44 recurrences, and 40 deaths.
†
Tumors with combined TOP2A amplification and CEP17 duplication.